Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
Pearl Toh, 5 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.

Bisphosphonate ‘holiday’ tied to increased fracture risk

Roshini Claire Anthony
10 Nov 2017

Women who temporarily or permanently stop taking bisphosphonates (drug holiday) for an extended period of time may have an increased risk of hip fractures, findings from a recent population-based study revealed.

“[A] bisphosphonate drug holiday greater than 2 years was associated with a significantly increased risk for hip fracture of up to 39 percent compared with continued bisphosphonate use,” said study lead author Professor Jeffrey Curtis who presented the findings at the annual meeting of the ACR/ARHP* held in San Diego, California, US, on behalf of himself and his fellow investigators from the University of Alabama at Birmingham, Alabama, US.

Compared with current users (crude incidence rate, 9.6 per 1,000 person-years), women who had ceased bisphosphonate therapy for more than 2 and up to 3 years had the highest rate of fracture incidence (crude incidence rate, 15.7 per 1,000 person-years; adjusted hazard ratio [adjHR], 1.39). [ACR/ARHP 2017, abstract 828]

Women who had ceased bisphosphonate therapy for >0 to ≤3 months, >3 months to ≤1 year, and >1 to ≤2 years also had an increased risk of hip fracture (adjHR, 1.29, 1.12, and 1.21, respectively; crude incidence rate, 13.1, 12.0, and 13.3 per 1,000 person-years, respectively).

Using Medicare data from 2006 to 2014, researchers identified 156,236 women (mean age, 78.5 years) who were long-term users of bisphosphonate therapy and were ≥80 percent treatment-adherent for ≥3 years at baseline. Patients who used other bone therapies such as denosumab, oestrogen, calcitonin, or teriparatide were excluded.

Over a median 2.1-year follow-up period, 40.1 percent (n=62,676) of patients ceased bisphosphonate therapy for ≥6 months, 12.7 percent (n=7,947) of whom later restarted bisphosphonate therapy. There were 3,745 hip fractures reported during the follow-up period.

Hip fracture incidence was lowest among women currently on bisphosphonate therapy and increased with longer duration of drug holiday.

“Given FDA** warnings, drug holidays [temporary or permanent discontinuation] of bisphosphonates after long-term [3–5 years] continuous therapy is becoming increasingly common in the US,” said Curtis and colleagues.

“Our goal was to evaluate the risk of discontinuing therapy based on the length of the holiday, controlling for any possibly confounding factors, such as race, median income, rural or urban location, DXA scores, or comorbidities,” said Curtis.

“While the notion of a drug holiday has become commonplace in osteoporosis management, there’s a dearth of evidence on when we should consider restarting bisphosphonate therapy. The study’s findings may provide useful evidence to help guide rheumatologists as they plan long-term therapy for their patients dealing with low bone mass,” he added.  

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
Pearl Toh, 5 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.